First Time Disclosures from Rome

The First Time Disclosures session at ACS Fall 2024 in Denver, organized by the MEDI Division of ACS, presented 13 innovative small molecules in clinical development, including Novartis’ IWY357 and Vividion’s KEAP1 covalent activator.


Related News

First Time Disclosures from Rome

The First Time Disclosures session at ACS Fall 2024 in Denver, organized by the MEDI Division of ACS, presented 13 innovative small molecules in clinical development, including Novartis’ IWY357 and Vividion’s KEAP1 covalent activator.

© Copyright 2024. All Rights Reserved by MedPath